In vitro pharmacologic characterization of a cholinergic receptor on outer hair cells.
Acetylcholine (ACh) is the major neurotransmitter released from the efferent fibers in the cochlea onto the outer hair cells (OHCs). The type of ACh receptor on OHCs and the events subsequent to receptor activation are unclear. Therefore we studied the effect of agonists and antagonists of the ACh receptor on isolated OHCs from the guinea pig. OHCs were recorded from in whole cell voltage and current clamp configuration. ACh induced an increase in outward K+ current (IACh) which hyperpolarized the OHCs. No desensitization to ACh application was observed. Cs+ replaced K+ in carrying the IACh. The IACh is Ca(2+)-dependent, time and voltage sensitive, and different from the IKCa induced by depolarization of the membrane potential. When tested at 100 microM, several agonists also induced outward current responses (acetylcholine > suberyldicholine > or = carbachol > DMPP) whereas nicotine, cytisine and muscarine did not. The IACh response to 10 microM ACh was blocked by low concentrations of traditional and non-traditional-nicotinic antagonists (strychnine > curare > bicuculline > alpha-bungarotoxin > thimethaphan) and by higher concentrations of muscarinic antagonists (atropine > 4-DAMP > AF-DX 116 > pirenzepine). Pharmacologically, the ACh receptor on OHCs is nicotinic.
Department of Otolaryngology, Tulane University School of Medicine, New Orleans LA.
C
C
Erostegui
C H
CH
Norris
R P
RP
Bobbin
D000109:Acetylcholine / Q000494:pharmacology; D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001392:Azocines; D002038:Bungarotoxins / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D002794:Choline / Q000031:analogs & derivatives / Q000494:pharmacology; D018680:Cholinergic Antagonists; D003472:Curare / Q000494:pharmacology; D004246:Dimethylphenylpiperazinium Iodide / Q000494:pharmacology; D006168:Guinea Pigs; D018072:Hair Cells, Auditory, Outer / Q000187:drug effects / Q000378:metabolism*; D066298:In Vitro Techniques; D008564:Membrane Potentials / Q000187:drug effects; D009538:Nicotine / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D010890:Pirenzepine / Q000494:pharmacology; D011807:Quinolizines; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000378:metabolism*; D013331:Strychnine / Q000494:pharmacology; D014294:Trimethaphan / Q000494:pharmacology; D000093843:Quinolizidine Alkaloids
D000109:Acetylcholine; D000470:Alkaloids; D001285:Atropine; D001392:Azocines; D002038:Bungarotoxins; D002217:Carbachol; D002794:Choline; D018680:Cholinergic Antagonists; D003472:Curare; D004246:Dimethylphenylpiperazinium Iodide; D009538:Nicotine; D010880:Piperidines; D010890:Pirenzepine; D011807:Quinolizines; D011950:Receptors, Cholinergic; D013331:Strychnine; D014294:Trimethaphan; C009335:subecholine; C004712:cytisine; D000093843:Quinolizidine Alkaloids; C042375:4-diphenylacetoxy-1,1-dimethylpiperidinium; C017774:trimethaphan camsylate